Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline
€129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026
… trial in 2022. RNA base-editing platform technologies – Axiomer ® and Trident ® ProQR has been further optimizing the Axiomer ® Editing Oligonucleotide (EON) designs and shown … will develop selected genetic eye disease targets with Axiomer ® , and will provide further guidance on this in H2 …
… with Lilly highlights significant potential of ProQR’s Axiomer ® RNA base-editing platform and strengthens financial … 18, 2021 to highlight clinical stage pipeline programs and Axiomer ® RNA editing platform LEIDEN, Netherlands & … the partnership we entered into with Lilly around our Axiomer RNA base-editing platform and the appointment of …
Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022
Phase 2/3 Sirius and Celeste clinical trials of ultevur
… in the lives of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing … nucleotides in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine …
ProQR will host a virtual Investor and Analyst Event highlighting its pipeline entitled:
“Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810”